ARYx Therapeutics
ARYx Therapeutics was a clinical-stage pharmaceutical company that used a proprietary retrometabolic chemistry platform to develop safer oral therapies for chronic diseases; it is now delisted and appears defunct.
- Company typePrivate
- Founded1997
- HeadquartersFremont, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
ARYx Therapeutics firmographics
Firmographics- Name
- ARYx Therapeutics
- Website
- https://aryx.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Unknown
- Headcount range
- 51–100 employees
- Short description
- ARYx Therapeutics was a clinical-stage pharmaceutical company that used a proprietary retrometabolic chemistry platform to develop safer oral therapies for chronic diseases; it is now delisted and appears defunct.
- Ownership category
- akta.pro rank
ARYx Therapeutics industry classification
Industry- Product category
- Pharmaceutical R&D
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where ARYx Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Fremont
- HQ country
- United States
- HQ region
- North America
Markets served
ARYx Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
ARYx Therapeutics product offering
Product offeringCore offering
ARYx Therapeutics applied its proprietary retrometabolic drug design chemistry to reformulate existing oral small-molecule drugs, producing safer, more tolerable versions of therapies intended for chronic disease indications. The company focused on improving the safety and pharmacokinetic profile of known active pharmaceutical ingredients rather than discovering novel molecular entities.
Differentiator
Problem solved
Functional benefit
Companies that use ARYx Therapeutics
Customer profileIdeal customer profiles1 record
ARYx Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ARYx Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Jazz Pharmaceuticals: Specialty pharma built around reformulated/repurposed therapies for chronic and CNS conditions; comparable business-model logic to ARYx's retrometabolic approach of extracting more value from differentiated chronic-disease oral therapies.
- Myriad Genetics: Public specialty pharma/diagnostics company from the same era that similarly leveraged proprietary science platforms to develop and commercialize differentiated therapies; broader incumbent versus ARYx's narrower chemistry-platform focus.
Direct peers
- Salix Pharmaceuticals: Specialty pharma focused on gastrointestinal and related chronic-disease therapies; comparable to ARYx in scale and therapeutic-area orientation toward oral chronic-disease drugs developed by smaller public specialty pharma.
- Penwest Pharmaceuticals: Small specialty pharma developing oral modified-release and reformulated chronic-disease therapies; directly comparable to ARYx in targeting improved oral drug profiles for chronic conditions.
- Neurogen Corporation: Clinical-stage small-molecule drug developer that was similarly backed by healthcare VCs and traded publicly; comparable to ARYx as a peer specialty pharma from the same 1990s-2000s venture cohort.
- Barrier Therapeutics: Small-cap specialty pharma that developed and commercialized prescription therapies for chronic conditions; similar profile to ARYx as a venture-backed, NASDAQ-listed clinical/specialty pharma of the same era.
- Avigen: Clinical-stage biotech of similar vintage and size backed by healthcare VCs; comparable as a peer venture-backed clinical developer that ultimately wound down commercial operations.
Emerging players
- Esperion Therapeutics: Late-stage clinical developer of oral therapies for chronic cardiometabolic disease; relevant emerging peer in the oral chronic-disease specialty pharma space ARYx targeted.
Market position
Customer concentration
ARYx Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ARYx Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
ARYx Therapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ARYx Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ARYx Therapeutics
What does ARYx Therapeutics do?
ARYx Therapeutics applied its proprietary retrometabolic drug design chemistry to reformulate existing oral small-molecule drugs, producing safer, more tolerable versions of therapies intended for chronic disease indications. The company focused on improving the safety and pharmacokinetic profile of known active pharmaceutical ingredients rather than discovering novel molecular entities.
When was ARYx Therapeutics founded?
ARYx Therapeutics was founded in 1997. It employs 51 to 100 people.
Where is ARYx Therapeutics based?
ARYx Therapeutics is headquartered in Fremont, United States, in the North America region.
Who are ARYx Therapeutics's main competitors?
Broad incumbents on record are Jazz Pharmaceuticals and Myriad Genetics. Direct peers are Salix Pharmaceuticals, Penwest Pharmaceuticals, Neurogen Corporation, Barrier Therapeutics and Avigen. Esperion Therapeutics is listed as an emerging player.
Does ARYx Therapeutics have an API?
No public API is recorded for ARYx Therapeutics.
What industry is ARYx Therapeutics in?
ARYx Therapeutics's product category is Pharmaceutical R&D. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 3254 and its SIC code is 2834.